17945

    543064

    COHANCE

    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    Cohance Lifesciences Ltd Share Price Today

    COHANCE LIFESCIENCES LTD is currently trading at ₹425, down by ₹0.29 from the previous close. The stock touched an intraday high of ₹427.55 and a low of ₹421.45 during the latest trading session. Over the past one year, COHANCE LIFESCIENCES LTD has delivered a loss of 57.35%, while the stock has declined 6.76% in the last one month.

    Cohance Lifesciences Ltd performance

    Today’s low Today’s high
    ₹ 421.45 ₹ 427.55
    ₹ 423.10
    52 week low 52 week high
    ₹ 266.70 ₹ 1038.90
    ₹ 423.10
    Open Price ₹ 426.00
    Prev. Close ₹ 425.30
    Volume (Shares) 68065.00
    Total traded value ₹ 287.98
    Upper Circuit ₹ 510.35
    Lower Circuit ₹ 340.25
    info

    Investment Returns

    Over 1 Month -6.76% Over 3 Months -11.99% Over 6 Months 11.53% Over 1 Year -57.35%
    Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    Cohance Lifesciences Ltd fundamentals


    • Market cap (Cr) 16,186.40
    • P/E Ratio (TTM) 71.19
    • Beta 0.85
    • Book Value / share 117.10
    • Return on equity 12.51%
    • EPS (TTM) 6.54
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 34.56
    info icon alternate text
    • Market cap (Cr) 16,199.80
    • P/E Ratio (TTM) 71.19
    • Beta 0.89
    • Book Value / share 117.10
    • Return on equity 12.51%
    • EPS (TTM) 6.54
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 34.56
    info icon alternate text

    Cohance Lifesciences Ltd Financials

    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 567.55
    Operating Expense 493.81
    Net Profit 34.56
    Net Profit Margin (%) 6.08
    Earnings Per Share (EPS) 0.90
    EBITDA 99.27
    Effective Tax Rate (%) 38.76
    Particulars DEC 2025 (Values in Cr)
    Revenue 481.58
    Operating Expense 417.41
    Net Profit 47.29
    Net Profit Margin (%) 9.81
    Earnings Per Share (EPS) 1.24
    EBITDA 104.04
    Effective Tax Rate (%) 27.72
    Particulars SEP 2025 (Values in Cr)
    Revenue 497.79
    Operating Expense 403.37
    Net Profit 94.29
    Net Profit Margin (%) 18.94
    Earnings Per Share (EPS) 2.46
    EBITDA 157.16
    Effective Tax Rate (%) 21.89
    Particulars JUN 2025 (Values in Cr)
    Revenue 483.58
    Operating Expense 417.54
    Net Profit 52.57
    Net Profit Margin (%) 10.87
    Earnings Per Share (EPS) 1.38
    EBITDA 109.20
    Effective Tax Rate (%) 25.99
    Particulars MAR 2025 (Values in Cr)
    Revenue 768.57
    Operating Expense 595.38
    Net Profit 122.77
    Net Profit Margin (%) 15.97
    Earnings Per Share (EPS) 3.22
    EBITDA 215.18
    Effective Tax Rate (%) 25.86
    Particulars MAR 2026 (Values in Cr)
    Revenue 2030.50
    Operating Expense 1732.13
    Net Profit 228.71
    Net Profit Margin (%) 11.26
    Earnings Per Share (EPS) 5.98
    EBITDA 469.66
    Effective Tax Rate (%) 27.07
    Particulars MAR 2025 (Values in Cr)
    Revenue 2504.43
    Operating Expense 1903.43
    Net Profit 491.18
    Net Profit Margin (%) 19.61
    Earnings Per Share (EPS) 12.89
    EBITDA 833.27
    Effective Tax Rate (%) 24.44
    Particulars MAR 2024 (Values in Cr)
    Revenue 1051.35
    Operating Expense 707.54
    Net Profit 296.47
    Net Profit Margin (%) 28.19
    Earnings Per Share (EPS) 11.65
    EBITDA 462.47
    Effective Tax Rate (%) 25.96
    Particulars MAR 2023 (Values in Cr)
    Revenue 1330.08
    Operating Expense 795.24
    Net Profit 432.60
    Net Profit Margin (%) 32.52
    Earnings Per Share (EPS) 16.99
    EBITDA 635.24
    Effective Tax Rate (%) 25.33
    Particulars MAR 2022 (Values in Cr)
    Revenue 1320.22
    Operating Expense 785.56
    Net Profit 558.10
    Net Profit Margin (%) 42.27
    Earnings Per Share (EPS) 21.92
    EBITDA 767.78
    Effective Tax Rate (%) 22.74
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 66.64
    ROE % 12.50
    ROCE % 13.56
    Total Debt to Total Equity 0.09
    EBITDA Margin 32.81
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 80.56
    ROE % 14.11
    ROCE % 18.69
    Total Debt to Total Equity 0.04
    EBITDA Margin 40.22
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 68.16
    ROE % 25.21
    ROCE % 33.22
    Total Debt to Total Equity 0.05
    EBITDA Margin 46.30
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 59.99
    ROE % 29.79
    ROCE % 40.62
    Total Debt to Total Equity 0.09
    EBITDA Margin 48.55
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 46.38
    ROE % 35.78
    ROCE % 40.45
    Total Debt to Total Equity 0.16
    EBITDA Margin 50.61
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 90.95
    ROE % 12.51
    ROCE % 15.94
    Total Debt to Total Equity 0.04
    EBITDA Margin 38.09
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 79.67
    ROE % 15.70
    ROCE % 20.80
    Total Debt to Total Equity 0.04
    EBITDA Margin 43.99
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 68.72
    ROE % 26.46
    ROCE % 34.28
    Total Debt to Total Equity 0.05
    EBITDA Margin 47.76
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 59.74
    ROE % 43.17
    ROCE % 51.45
    Total Debt to Total Equity 0.09
    EBITDA Margin 58.33
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 41.84
    ROE % 33.40
    ROCE % 38.83
    Total Debt to Total Equity 0.18
    EBITDA Margin 45.29
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 88.67
    Total Assets 3031.75
    Total Liabilities 3031.75
    Total Equity 1840.64
    Share Outstanding 25
    Price to Book Ratio 12.75
    Return on Assets (%) 8.83
    Return on Capital (%) 13.96
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 50.49
    Total Assets 2254.08
    Total Liabilities 2254.08
    Total Equity 2050.66
    Share Outstanding 25
    Price to Book Ratio 8.49
    Return on Assets (%) 13.32
    Return on Capital (%) 14.37
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 68.01
    Total Assets 1965.74
    Total Liabilities 1965.74
    Total Equity 1735.18
    Share Outstanding 25
    Price to Book Ratio 6.88
    Return on Assets (%) 20.92
    Return on Capital (%) 22.79
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 47.30
    Total Assets 1829.58
    Total Liabilities 1829.58
    Total Equity 1527.18
    Share Outstanding 25
    Price to Book Ratio 10.34
    Return on Assets (%) 24.80
    Return on Capital (%) 27.97
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 9.65
    Total Assets 1474.47
    Total Liabilities 1474.47
    Total Equity 1180.79
    Share Outstanding 25
    Price to Book Ratio 11.84
    Return on Assets (%) 24.57
    Return on Capital (%) 27.41
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 22.62
    Total Assets 2587.81
    Total Liabilities 2587.81
    Total Equity 2315.55
    Share Outstanding 25
    Price to Book Ratio 12.75
    Return on Assets (%) 10.49
    Return on Capital (%) 11.39
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 21.73
    Total Assets 2214.88
    Total Liabilities 2214.88
    Total Equity 2028.35
    Share Outstanding 25
    Price to Book Ratio 8.49
    Return on Assets (%) 13.38
    Return on Capital (%) 14.34
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 46.23
    Total Assets 1958.33
    Total Liabilities 1958.33
    Total Equity 1749.38
    Share Outstanding 25
    Price to Book Ratio 6.88
    Return on Assets (%) 22.09
    Return on Capital (%) 23.79
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 32.95
    Total Assets 1804.88
    Total Liabilities 1804.88
    Total Equity 1520.69
    Share Outstanding 25
    Price to Book Ratio 10.34
    Return on Assets (%) 30.92
    Return on Capital (%) 34.53
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 9.56
    Total Assets 1358.82
    Total Liabilities 1358.82
    Total Equity 1065.18
    Share Outstanding 25
    Price to Book Ratio 11.84
    Return on Assets (%) 22.71
    Return on Capital (%) 25.58
    Particulars MAR 2025 (Values in Cr)
    Net Income 343.92
    Cash from Operations 371.60
    Cash from Investing -255.30
    Cash from Financing 3.32
    Net change in Cash 36.18
    Free Cash Flow 527.31
    Particulars MAR 2024 (Values in Cr)
    Net Income 405.67
    Cash from Operations 468.43
    Cash from Investing -362.25
    Cash from Financing -13.80
    Net change in Cash -17.57
    Free Cash Flow 520.22
    Particulars MAR 2023 (Values in Cr)
    Net Income 559.72
    Cash from Operations 602.95
    Cash from Investing -195.00
    Cash from Financing -241.95
    Net change in Cash 20.23
    Free Cash Flow 888.86
    Particulars MAR 2022 (Values in Cr)
    Net Income 667.58
    Cash from Operations 514.25
    Cash from Investing -136.20
    Cash from Financing -156.41
    Net change in Cash 37.38
    Free Cash Flow 589.44
    Particulars MAR 2021 (Values in Cr)
    Net Income 467.67
    Cash from Operations 491.98
    Cash from Investing -311.39
    Cash from Financing -75.66
    Net change in Cash -4.51
    Free Cash Flow 602.82
    Particulars MAR 2025 (Values in Cr)
    Net Income 351.35
    Cash from Operations 381.41
    Cash from Investing -320.94
    Cash from Financing 20.81
    Net change in Cash 0.90
    Free Cash Flow 520.31
    Particulars MAR 2024 (Values in Cr)
    Net Income 400.42
    Cash from Operations 484.72
    Cash from Investing -362.40
    Cash from Financing -39.99
    Net change in Cash -26.19
    Free Cash Flow 536.60
    Particulars MAR 2023 (Values in Cr)
    Net Income 579.39
    Cash from Operations 638.60
    Cash from Investing -236.86
    Cash from Financing -243.14
    Net change in Cash 12.81
    Free Cash Flow 783.21
    Particulars MAR 2022 (Values in Cr)
    Net Income 722.44
    Cash from Operations 421.63
    Cash from Investing -90.36
    Cash from Financing -156.41
    Net change in Cash 23.11
    Free Cash Flow 496.82
    Particulars MAR 2021 (Values in Cr)
    Net Income 413.97
    Cash from Operations 439.16
    Cash from Investing -257.65
    Cash from Financing -76.55
    Net change in Cash -4.48
    Free Cash Flow 550.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 33.64 13.96 1.62 257.79 23.12 38.85
    BLISS GVS PHARMA LTD 454.10 36.50 4.03 4816.01 118.35 552.90
    CIPLA LTD. 1466.00 33.09 3.43 118430.12 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 465.55 21.78 3.36 1370.16 256.40 482.70
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 33.64 23.52 4.33 257.79 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 518.30 23.23 4.04 1498.44 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8090.05 105.72 23.17 20225.13 7630.00 9850.00
    BLISS GVS PHARMA LTD 454.10 49.09 4.16 4816.01 118.35 552.90

    Cohance Lifesciences Ltd shareholding pattern

    Holding
    15.92%
    57.48%
    6.49%
    20.08%
    94.56%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    Cohance Lifesciences Ltd Technicals Summary

    423.10 -0.51 redarrow
    red-green-graph indicator
    15 Bearish
    1 Bullish
    • 5 Days 427.80
    • 26 Days 435.10
    • 10 Days 431.00
    • 50 Days 431.30
    • 12 Days 432.10
    • 100 Days 435.80
    • 20 Days 434.70
    • 200 Days 516.10
    430.08 PIVOT
    First Support 426.47 First Resistance 434.92 Second Support 421.63 Second Resistance 438.53 Third Support 418.02 Third Resistance 443.37
    RSI 44.68 ADX 31.18 MACD -3.06 Williams % R -77.19 Commodity Channel Index (CCI) -97.31
    Date 2026-07-30 Week 183479.00 Same Day 146002.00 Month 223284.00
    1 Year 0.86 3 Year 0.63
    Over 1 Month
    -6.76% down
    Over 1 Year
    -57.35% down
    Over 3 Months
    -11.99% down
    Over 3 Years
    -4.92% down
    Over 6 Months
    11.53% down
    Over 5 Years
    -3.42% down

    Cohance Lifesciences Ltd Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    09 Sep 2022 5.0 Special 12 Sep 2022 Equity shares
    09 Sep 2022 1.0 Interim 12 Sep 2022 Equity shares
    13 May 2022 1.0 Special 17 May 2022 Equity shares
    13 May 2022 1.0 Interim 2 17 May 2022 Equity shares
    15 Feb 2022 2.0 Special 16 Feb 2022 Equity shares
    15 Feb 2022 1.0 Interim 16 Feb 2022 Equity shares
    13 Aug 2021 1.0 Final 17 Aug 2021 Equity shares
    17 Feb 2021 1.0 Interim 18 Feb 2021 Equity shares
    Ex-Date Ex-Bonus Ratio
    28 Sep 2020 25 Sep 2020 1:1
    Dividend date Dividend amount Dividend type Record date Instrument type
    09 Sep 2022 5.0 Special 12 Sep 2022 Equity shares
    09 Sep 2022 1.0 Interim 12 Sep 2022 Equity shares
    13 May 2022 1.0 Special 17 May 2022 Equity shares
    13 May 2022 1.0 Interim 2 17 May 2022 Equity shares
    15 Feb 2022 2.0 Special 16 Feb 2022 Equity shares
    15 Feb 2022 1.0 Interim 16 Feb 2022 Equity shares
    13 Aug 2021 1.0 Final 17 Aug 2021 Equity shares
    17 Feb 2021 1.0 Interim 18 Feb 2021 Equity shares
    Ex-Date Ex-Bonus Ratio
    28 Sep 2020 25 Sep 2020 1:1

    Top Gainers

    Top Losers

    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Cohance Lifesciences Ltd?

    Answer Field

    Cohance Lifesciences Ltd share price is for NSE ₹ 425.00 & for BSE ₹ 425.15 as on Jul 31 2026 02:49 PM.

    What is the Market Cap of Cohance Lifesciences Ltd Share?

    Answer Field

    The market cap of Cohance Lifesciences Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 31 2026 02:49 PM.

    What is the 52 Week High and Low of Cohance Lifesciences Ltd?

    Answer Field

    The 52 Week High and Low of Cohance Lifesciences Ltd for NSE is ₹ 1,038.90 and ₹ 266.70 and for BSE is ₹ 1,038.00 and ₹ 267.85.

    What is 1 year return for Cohance Lifesciences Ltd?

    Answer Field

    The 1 year returns on the stock has been -57.35%.

    What is the P/E Ratio of Cohance Lifesciences Ltd Share?

    Answer Field

    As on Jul 31 2026 02:49 PM the price-to-earnings (PE) ratio for Cohance Lifesciences Ltd share is 71.19.

    What is the PB ratio of Cohance Lifesciences Ltd Share?

    Answer Field

    As on Jul 31 2026 02:49 PM, the price-to-book (PB) ratio for Cohance Lifesciences Ltd share is 117.10.

    How to Buy Cohance Lifesciences Ltd Share?

    Answer Field

    You can trade in Cohance Lifesciences Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Cohance Lifesciences Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Cohance Lifesciences Ltd shares on the Bajaj Broking app, follow these steps:

    1. Login to the Bajaj Broking App

    2. Click on the Search Icon

    3. Search “Cohance Lifesciences Ltd”

    4. Click on the BUY icon

    5. Place a buy order specifying the desired quantity of shares.

    6. Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |